NGNE (Neurogene) Tariff Resilience Score: 8/10 (As of Jun. 30, 2026)


NGNE Neurogene Inc NGNE
12 GF Score
Price $31.31
! 4 Warning Signs
View Full Analysis

What is Neurogene Tariff Resilience Score?

Neurogene NGNE -2.57% 12 Tariff Resilience Score is 8 as of Jun. 30, 2026. GuruFocus rates NGNE with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 1,375 Biotechnology companies, Neurogene ranks better than 98.69% on this metric.

Neurogene has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Neurogene has Neurogene's focus on biotechnology and R&D, primarily within the U.S., limits its exposure to tariffs. The company has minimal reliance on international supply chains, and its products are less likely to be affected by trade policies. Industry-specific exemptions further enhance resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Neurogene might have Highly Resilient.

Neurogene  (NAS:NGNE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Neurogene Tariff Resilience Score Related Terms

NGNE vs STRO, OCGN, CBIO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Neurogene's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurogene Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurogene's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Neurogene's Tariff Resilience Score falls into.


NGNE
12GF Score
Neurogene Inc NGNE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Neurogene (NGNE) has a Tariff Resilience Score of 8 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Neurogene ranks #18 out of 1375 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Neurogene's Tariff Resilience Score too high?
Neurogene's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Neurogene's value of 8 is 100% above this industry median. Based on the distribution chart, Neurogene ranks #18 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neurogene has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Neurogene's Tariff Resilience Score compare to STRO and OCGN?
According to the Biotechnology industry distribution chart, Neurogene ranks #18 out of 1375 companies for Tariff Resilience Score. This places Neurogene in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Neurogene's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurogene's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurogene's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurogene stock overvalued right now?
Neurogene (NGNE) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Neurogene's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Neurogene (NGNE), the current Tariff Resilience Score is 8 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurogene Business Description

Other Exchanges UU8:Germany
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
12GF Score

Get the complete analysis for NGNE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.31
Price